257 related articles for article (PubMed ID: 10523846)
1. Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately.
Batsché E; Crémisi C
Oncogene; 1999 Oct; 18(41):5662-71. PubMed ID: 10523846
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression and activation in the same cell type of the human c-MYC promoter by the retinoblastoma gene protein: antagonisation of both effects by SV40 T antigen.
Batsché E; Lipp M; Cremisi C
Oncogene; 1994 Aug; 9(8):2235-43. PubMed ID: 8036009
[TBL] [Abstract][Full Text] [Related]
3. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
Adnane J; Robbins PD
Oncogene; 1995 Jan; 10(2):381-7. PubMed ID: 7838535
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
[TBL] [Abstract][Full Text] [Related]
5. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
[TBL] [Abstract][Full Text] [Related]
6. Cellular and viral trans-acting factors modulate N-myc2 promoter activity in woodchuck liver tumors.
Flajolet M; Gegonne A; Ghysdael J; Tiollais P; Buendia MA; Fourel G
Oncogene; 1997 Aug; 15(9):1103-10. PubMed ID: 9285565
[TBL] [Abstract][Full Text] [Related]
7. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
Luo Q; Li J; Cenkci B; Kretzner L
Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
[TBL] [Abstract][Full Text] [Related]
8. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc.
Mazure NM; Chauvet C; Bois-Joyeux B; Bernard MA; Nacer-Chérif H; Danan JL
Cancer Res; 2002 Feb; 62(4):1158-65. PubMed ID: 11861398
[TBL] [Abstract][Full Text] [Related]
9. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
10. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
Yang W; Shen J; Wu M; Arsura M; FitzGerald M; Suldan Z; Kim DW; Hofmann CS; Pianetti S; Romieu-Mourez R; Freedman LP; Sonenshein GE
Oncogene; 2001 Mar; 20(14):1688-702. PubMed ID: 11313917
[TBL] [Abstract][Full Text] [Related]
11. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells.
Kim DW; Gazourian L; Quadri SA; Romieu-Mourez R; Sherr DH; Sonenshein GE
Oncogene; 2000 Nov; 19(48):5498-506. PubMed ID: 11114727
[TBL] [Abstract][Full Text] [Related]
12. Bax is a transcriptional target and mediator of c-myc-induced apoptosis.
Mitchell KO; Ricci MS; Miyashita T; Dicker DT; Jin Z; Reed JC; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6318-25. PubMed ID: 11103792
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells.
Yang J; Deng X; Deng L; Gu H; Fan W; Cao Y
J Exp Clin Cancer Res; 2004 Sep; 23(3):495-506. PubMed ID: 15595642
[TBL] [Abstract][Full Text] [Related]
14. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
15. RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2.
Batsché E; Muchardt C; Behrens J; Hurst HC; Crémisi C
Mol Cell Biol; 1998 Jul; 18(7):3647-58. PubMed ID: 9632747
[TBL] [Abstract][Full Text] [Related]
16. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
Cziepluch C; Wenzel A; Schürmann J; Schwab M
Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
[TBL] [Abstract][Full Text] [Related]
17. A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence.
Alvaro-Blanco J; Martínez-Gac L; Calonge E; Rodríguez-Martínez M; Molina-Privado I; Redondo JM; Alcamí J; Flemington EK; Campanero MR
Carcinogenesis; 2009 Mar; 30(3):440-8. PubMed ID: 19126644
[TBL] [Abstract][Full Text] [Related]
18. The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in fibroblasts.
Liu SL; Rand A; Kelm RJ; Getz MJ
Oncogene; 2000 Jul; 19(30):3352-62. PubMed ID: 10918592
[TBL] [Abstract][Full Text] [Related]
19. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc.
Sasaki T; Suzuki H; Yagi K; Furuhashi M; Yao R; Susa S; Noda T; Arai Y; Miyazono K; Kato M
Cancer Res; 2003 Feb; 63(4):801-6. PubMed ID: 12591729
[TBL] [Abstract][Full Text] [Related]
20. Position and orientation independent transactivation by c-Myc.
Packham G; Bello-Fernandez C; Cleveland JL
Cell Mol Biol Res; 1994; 40(7-8):699-706. PubMed ID: 7787888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
